Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Monoclonal Antibodies Alzheimer's Disease Combination Therapy Eli Lilly Oncology Novo Nordisk Immunotherapy GLP-1 Drugs

3 ARTICLES

2d ago

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

The move lets eligible patients at 10 community hospitals start daraxonrasib before full approval because a phase 3 trial roughly doubled survival for treated patients.

4 ARTICLES

5d ago

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

3 ARTICLES

5d ago

Sionna Halts SION-719 After Mid-Stage Cystic Fibrosis Trial Misses Key Biomarker

6 ARTICLES

last wk.

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

5 ARTICLES

2w ago

FDA Advisers Find Replimune’s RP1 Trial Results Clinically Meaningful

4 ARTICLES

2w ago

UK Clears Aficamten (MYQORZO) for Symptomatic Obstructive Hypertrophic Cardiomyopathy

3 ARTICLES

2w ago

Snake Blood Proteins Could Yield Far More Potent, Broader Antivenoms

4 ARTICLES

2w ago

Dupixent Surge Lets Sanofi Reset Strategy as Regeneron Posts Strong Quarter

11 ARTICLES

2w ago

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

7 ARTICLES

2w ago

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

3 ARTICLES

2w ago

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

3 ARTICLES

3w ago

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

3 ARTICLES

3w ago

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

9 ARTICLES

3w ago

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

31 ARTICLES

4w ago

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

3 ARTICLES

4w ago

Donanemab Slows Alzheimer's Decline, New AAIC Data Show

Drug Development

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

Sionna Halts SION-719 After Mid-Stage Cystic Fibrosis Trial Misses Key Biomarker

FDA Approves Orzeyful as First Orexin Agonist for Narcolepsy Type 1

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

Eli Lilly Opens Limited Early Access to Experimental Obesity Drug Retatrutide

Pfizer Raises 2026 Revenue Floor After Q2 Beat as Covid Sales Fall

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

FDA Advisers Find Replimune’s RP1 Trial Results Clinically Meaningful

UK Clears Aficamten (MYQORZO) for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Never miss stories about

Drug Development

Snake Blood Proteins Could Yield Far More Potent, Broader Antivenoms

Dupixent Surge Lets Sanofi Reset Strategy as Regeneron Posts Strong Quarter

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

EU Advisers Back Susvimo Implant as New Option for Wet Age‑Related Macular Degeneration

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

FDA Approves First Oral PCSK9 Pill, Merck’s Lipfendra

Donanemab Slows Alzheimer's Decline, New AAIC Data Show

Never miss stories about

Drug Development